Comparison of Three Graft-versus-Host Disease Prophylaxis Strategies after T Cell-Replete Haploidentical Hematopoietic Transplantation: Tacrolimus versus Calcineurin Inhibitors plus Mycophenolate Mofetil versus Sirolimus plus Mycophenolate Mofetil

被引:0
作者
Esquirol, Albert [1 ]
Pascual, Maria Jesus [2 ]
Montoro, Juan [3 ]
Pinana, Jose Luis [4 ]
Ferra, Christelle [5 ]
Herruzo, Beatriz [2 ]
Garcia-Cadenas, Irene [1 ]
Balaguer, Aitana [3 ]
Perez, Ariadna [4 ]
Huguet, Maria [5 ]
Redondo, Sara [1 ]
Villalba, Marta [3 ]
Hernandez-Boluda, Juan Carlos [4 ]
Chorao, Pedro [3 ]
Hernani, Rafael [4 ]
Sanz, Jaime [3 ]
Solano, Carlos [4 ]
Sierra, Jorge [1 ]
Martino, Rodrigo [1 ]
机构
[1] Univ Autonoma Barcelona, Hosp Santa Creu & St Pau, IIB St Pau & Jose Carreras Leukemia Res Inst, Hematol Dept, Barcelona, Spain
[2] Hosp Reg Univ, Hematol Dept, Malaga, Spain
[3] Hosp Universitari & Politecn La Fe, Dept Hematol, Valencia, Spain
[4] Hosp Clin Univ, Hematol Dept, Valencia, Spain
[5] Hosp Badalona Germans Trias & Pujol, Hematol Dept, Badalona, Spain
来源
TRANSPLANTATION AND CELLULAR THERAPY | 2024年 / 30卷 / 10期
关键词
Haploidentical stem cell; transplantation; TBF conditioning; Haploidentical GVHD; prophylaxis; Tacrolimus versus sirolimus; BONE-MARROW-TRANSPLANTATION; STANDARD-OF-CARE; BLOOD STEM-CELLS; POSTTRANSPLANT CYCLOPHOSPHAMIDE; GVHD PROPHYLAXIS; HEMATOLOGIC MALIGNANCIES; PHASE-II; DONOR; METHOTREXATE; CYCLOSPORINE;
D O I
10.1016/j.jtct.2024.07.027
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Since the introduction of post-transplantation cyclophosphamide (PTCy), haploidentical hematopoietic stem cell transplantation (haploSCT) has become a real alternative for patients who lack other eligible donors. The standard graft-versus-host disease (GVHD) prophylaxis after PTCy has been a calcineurin inhibitor (CNI) plus mycophenolate mofetil (MMF) (up to day +35), but promising results with sirolimus (with or without MMF) and single-agent tacrolimus have been published recently. This multicenter retrospective study compared the outcomes of 372 adult haploSCT recipients who received conditioning with thiotepa, busulfan, and fludarabine (TBF), PTCy, and additional GVHD prophylaxis with 1 of 3 strategies: cohort A, single-agent tacrolimus (n = 222); cohort B, CNI + MMF (n = 49); or cohort C, sirolimus + MMF (n = 101). No differences among the 3 cohorts were found in terms of grade II-IV acute GVHD (20% in cohort A, 25% in cohort B, and 30% in cohort C) or grade III-IV acute GVHD (9%, 6%, and 15%, respectively) at 100 days; however, cohort A had the lowest incidence of overall chronic GVHD (24%, 47%, and 52%, respectively; P = .001) and moderatesevere chronic GVHD (13%, 35%, and 33%, respectively; P = .001). There were no differences in 3-year overall survival, progression-free survival, nonrelapse mortality, or relapse among the 3 cohorts. Overall, our study suggests that single-agent tacrolimus, CNI + MMF, and sirolimus + MMF GVHD prophylaxis lead to similar outcomes following haploSCT with TBF and PTCy, with a low incidence of grade III-IV acute GVHD, although possible differences in chronic GVHD require further investigation. (c) 2024 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
引用
收藏
页码:1025e1 / 1025e14
页数:14
相关论文
共 42 条
[1]   The combination of sirolimus plus tacrolimus improves outcome after reduced-intensity conditioning, unrelated donor hematopoietic stem cell transplantation compared with cyclosporine plus mycofenolate [J].
Antonio Perez-Simon, Jose ;
Martino, Rodrigo ;
Parody, Rocio ;
Cabrero, Monica ;
Lopez-Corral, Lucia ;
Valcarcel, David ;
Martinez, Carmen ;
Solano, Carlos ;
Vazquez, Lourdes ;
Marquez-Malaver, Francisco J. ;
Sierra, Jordi ;
Caballero, Dolores .
HAEMATOLOGICA, 2013, 98 (04) :526-532
[2]   Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation [J].
Armand, Philippe ;
Kim, Haesook T. ;
Logan, Brent R. ;
Wang, Zhiwei ;
Alyea, Edwin P. ;
Kalaycio, Matt E. ;
Maziarz, Richard T. ;
Antin, Joseph H. ;
Soiffer, Robert J. ;
Weisdorf, Daniel J. ;
Rizzo, J. Douglas ;
Horowitz, Mary M. ;
Saber, Wael .
BLOOD, 2014, 123 (23) :3664-3671
[3]   Unmanipulated haploidentical bone marrow transplantation and post-transplant cyclophosphamide for hematologic malignanices following a myeloablative conditioning: an update [J].
Bacigalupo, A. ;
Dominietto, A. ;
Ghiso, A. ;
Di Grazia, C. ;
Lamparelli, T. ;
Gualandi, F. ;
Bregante, S. ;
Van Lint, M. T. ;
Geroldi, S. ;
Luchetti, S. ;
Grasso, R. ;
Pozzi, S. ;
Colombo, N. ;
Tedone, E. ;
Varaldo, R. ;
Raiola, A. M. .
BONE MARROW TRANSPLANTATION, 2015, 50 :S37-S39
[4]   Graft versus host disease in unmanipulated haploidentical marrow transplantation with a modified post-transplant cyclophosphamide (PT-CY) regimen: an update on 425 patients [J].
Bacigalupo, Andrea ;
Raiola, Anna Maria ;
Dominietto, Alida ;
Di Grazia, Carmen ;
Gualandi, Francesca ;
Van Lint, Maria Teresa ;
Chiusolo, Patrizia ;
Laurenti, Luca ;
Sora, Federica ;
Giammarco, Sabrina ;
Angelucci, Emanuele .
BONE MARROW TRANSPLANTATION, 2019, 54 (Suppl 2) :708-712
[5]   Post-Transplantation Cyclophosphamide After HLA Identical Compared to Haploidentical Donor Transplant in Acute Myeloid Leukemia: A Study on Behalf of GETH-TC [J].
Bailen, Rebeca ;
Jesus Pascual-Cascon, Maria ;
Guerreiro, Manuel ;
Lopez-Corral, Lucia ;
Chinea, Anabelle ;
Bermudez, Arancha ;
Sampol, Antonia ;
Heras, Inmaculada ;
Garcia-Torres, Estefania ;
Torres, Melissa ;
Rifon Roca, Jose ;
Herruzo, Beatriz ;
Sanz, Jaime ;
Fonseca, Marta ;
Herrera, Pilar ;
Colorado, Mercedes ;
Bento, Leyre ;
Lopez-Godino, Oriana ;
Martin-Calvo, Carmen ;
Fernandez-Caldas, Paula ;
Marcos-Jubilar, Maria ;
Sanchez-Ortega, Isabel ;
Solano, Carlos ;
Noriega, Victor ;
Humala, Karem ;
Oarbeascoa, Gillen ;
Diez-Martin, Jose Luis ;
Kwon, Mi .
TRANSPLANTATION AND CELLULAR THERAPY, 2022, 28 (04) :204.e1-204.e10
[6]   T-cell replete haploidentical donor transplantation using post-transplant CY: an emerging standard-of-care option for patients who lack an HLA-identical sibling donor [J].
Bashey, A. ;
Solomon, S. R. .
BONE MARROW TRANSPLANTATION, 2014, 49 (08) :999-1008
[7]   Mobilized Peripheral Blood Stem Cells Versus Unstimulated Bone Marrow As a Graft Source for T-Cell-Replete Haploidentical Donor Transplantation Using Post-Transplant Cyclophosphamide [J].
Bashey, Asad ;
Zhang, Mei-Jie ;
McCurdy, Shannon R. ;
St Martin, Andrew ;
Argall, Trevor ;
Anasetti, Claudio ;
Ciurea, Stefan O. ;
Fasan, Omotayo ;
Gaballa, Sameh ;
Hamadani, Mehdi ;
Munshi, Pashna ;
Al Malki, Monzr M. ;
Nakamura, Ryotaro ;
O'Donnell, Paul V. ;
Perales, Miguel-Angel ;
Raj, Kavita ;
Romee, Rizwan ;
Rowley, Scott ;
Rocha, Vanderson ;
Salit, Rachel B. ;
Solh, Melhem ;
Soiffer, Robert J. ;
Fuchs, Ephraim Joseph ;
Eapen, Mary .
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (26) :3002-+
[8]   A phase 2 trial of GVHD prophylaxis with PTCy, sirolimus, and MMF after peripheral blood haploidentical transplantation [J].
Bejanyan, Nelli ;
Pidala, Joseph A. ;
Wang, Xuefeng ;
Thapa, Ram ;
Nishihori, Taiga ;
Elmariah, Hany ;
Lazaryan, Aleksandr ;
Khimani, Farhad ;
Davila, Marco L. ;
Mishra, Asmita ;
Faramand, Rawan ;
Jain, Michael D. ;
Ochoa, Leonel ;
Perez, Lia Elena ;
Liu, Hien ;
Alsina, Melissa ;
Kharfan-Dabaja, Mohamed A. ;
Fernandez, Hugo ;
Nieder, Michael L. ;
Locke, Frederick L. ;
Anasetti, Claudio ;
Ayala, Ernesto .
BLOOD ADVANCES, 2021, 5 (05) :1154-1163
[9]   Sirolimus and Mycophenolate Mofetil as Calcineurin Inhibitor-Free Graft-versus-Host Disease Prophylaxis for Reduced-Intensity Conditioning Umbilical Cord Blood Transplantation [J].
Bejanyan, Nelli ;
Rogosheske, John ;
DeFor, Todd E. ;
Lazaryan, Aleksandr ;
Arora, Mukta ;
Holtan, Shernan G. ;
Jacobson, Pamala A. ;
MacMillan, Margaret L. ;
Verneris, Michael R. ;
Blazar, Bruce R. ;
Weisdorf, Daniel J. ;
Wagner, John E. ;
Brunstein, Claudio G. .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2016, 22 (11) :2025-2030
[10]   Post-Transplantation CyclophosphamideBased Graft-versus-Host Disease Prophylaxis [J].
Bolanos-Meade, J. ;
Hamadani, M. ;
Wu, J. ;
Al Malki, M. M. ;
Martens, M. J. ;
Runaas, L. ;
Elmariah, H. ;
Rezvani, A. R. ;
Gooptu, M. ;
Larkin, K. T. ;
Shaffer, B. C. ;
El Jurdi, N. ;
Loren, A. W. ;
Solh, M. ;
Hall, A. C. ;
Alousi, A. M. ;
Jamy, O. H. ;
Perales, M. -A. ;
Yao, J. M. ;
Applegate, K. ;
Bhatt, A. S. ;
Kean, L. S. ;
Efebera, Y. A. ;
Reshef, R. ;
Clark, W. ;
DiFronzo, N. L. ;
Leifer, E. ;
Horowitz, M. M. ;
Jones, R. J. ;
Holtan, S. G. .
NEW ENGLAND JOURNAL OF MEDICINE, 2023, 388 (25) :2338-2348